• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.82% Nasdaq Up2.46%

    Cytokinetics, Incorporated (CYTK)

    -NasdaqCM
    7.20 Up 0.34(4.96%) 3:59PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Cytokinetics, Incorporated
    280 East Grand Avenue
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-624-3000
    Fax: 650-624-3010
    Website: http://www.cytokinetics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:92

    Business Summary 

    Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is involved in developing Tirasemtiv, a fast skeletal troponin activator that is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107 that is in Phase I for the treatment of spinal muscle atrophy; and Omecamtiv mecarbil, which is in Phase II clinical trials for the potential treatment of heart failure. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to advance novel therapies for diseases and medical conditions associated with muscle weakness. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cytokinetics, Incorporated

    Corporate Governance 
    Cytokinetics, Incorporated’s ISS Governance QuickScore as of Sep 1, 2015 is 8. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Robert I. Blum , 51
    Chief Exec. Officer, Pres, Director and Chief Exec. of the Biopharmaceutical Concern
    878.00K0.00
    Ms. Sharon A. Surrey-Barbari , 61
    Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. and Corp. Sec.
    562.00K0.00
    Ms. Bonnie A. Charpentier Ph.D., 63
    Sr. VP of Regulatory Affairs & Compliance
    407.00K0.00
    Mr. David W. Cragg , 59
    Sr. VP of HR
    388.00K0.00
    Dr. Fady Ibraham Malik M.D., Ph.D., FACC, 51
    Sr. VP of R&D
    524.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders